Aptamer Group develops novel antibody alternatives called Optimers, that can be used in research, diagnostics, and medicine. The company works with partners across the life science sector, including large pharmaceutical companies, such as AstraZeneca and Cancer Research UK.
Embedding the company at YSP in 2013 allowed Aptamer to take advantage of the available infrastructure at YSP and facilitated its continued growth, with multiple expansions of its lab and office footprint within the Biocentre building over the last nine years. Aptamer have been continually recruiting for new team members, with a staff expansion of over 40% over the past year.
In December 2021, the company successfully raised £10.8 million as part of its IPO. As a result, Aptamer Group is now entering its next stage of growth, with the move to larger premises within YSP that can accommodate the increasing staff numbers along with its expanding robotic discovery platform.
Dr Arron Tolley, CEO of Aptamer Group, said: “We are excited to begin the next phase of our journey in building Aptamer Group and the Optimer platform as a much-needed, robust alternative to antibodies to support the life science industry. We’re very grateful to YSP for supporting our growth to this stage, and looking forward to continuing to expand the team and the platform’s capacity with this move.”
Find out more about Aptamer Group on their website.
